Michelangelo M.
- Country
- Italy
- Department
- Department of Neuroscience
Research Overview
- Open-label extension study of KL1333 for long-term safety, tolerability, and efficacy in adults with primary mitochondrial disease
- Phase 2a Study on Safety, Tolerability, and Pharmacodynamics of OMT-28 in Patients with Primary Mitochondrial Disease-Associated Myopathy/Cardiomyopathy
- Long-term Evaluation of Safety, Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Empasiprubart in Adults with Multifocal Motor Neuropathy
Data & Insights
Has run more than one trial at 13 of 55 partner sites.
Specializations
Mitochondrial Disorders
This investigator specializes in treating primary mitochondrial diseases, with particular emphasis on MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes).
- Mitochondrial Disease Management
- MELAS Treatment Approaches
- Myopathy and Cardiomyopathy Care
The investigator focuses on innovative therapeutic approaches for mitochondrial disorders affecting multiple body systems.
Therapeutic Focus Areas
Primary research interests include addressing fatigue symptoms and cognitive function in patients with mitochondrial diseases.
- Fatigue Management
- Cognitive Enhancement
- Functional Strength Improvement
The investigator evaluates treatments targeting specific disease manifestations and their impact on daily living.
Clinical Expertise
Specialized in assessing inflammatory conditions associated with mitochondrial diseases and their treatment outcomes.
- Long-term Safety Assessment
- Treatment Tolerability
- Disease Biomarker Analysis
The investigator evaluates novel therapeutic compounds for rare mitochondrial disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.